Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Slides:

Advertisements

Similar presentations

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.

Advertisements

Discontinuation of medication after nonfatal event: MI

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

The MASS-DAC Study.

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Supplementary Table 1 Independent Predictors of 2-Year Mortality

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Copyright © 2013 American Medical Association. All rights reserved.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Presented by Dr. Leif Thuesen

Glenn N. Levine et al. JACC 2016;68:

Baseline characteristics of patients

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction P.-G. Chassot, A. Delabays, D.R. Spahn

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Coronary revascularisation rate (total 5

Figure 4 Observational studies on multiple treatment strategies

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

The recommended approach to patients with chronic obstructive pulmonary disease (COPD) presenting with dyspnoea. The recommended approach to patients with.

Tornado diagram of one-way deterministic sensitivity analysis.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Nat. Rev. Cardiol. doi: /nrcardio

Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. There.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

A Kaplan-Meier curve showing the cumulative incidence of the secondary NFE of TLR or de novo PCI during the 5-year follow-up (30 patients) (A) A heat map.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

DuyKhanh P. Ceppa, MD, Ian J. Welsby, MBBS, Tracy Y. Wang, MD, Mark W

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Comparison of the change in index of microcirculatory resistance (IMR) at each stage of the primary percutaneous coronary intervention (PPCI) for balloon.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Kaplan-Meier survival estimates for major cardiovascular events.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Propensity score-matching

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Forest plot illustrating the risk ratio of major bleeding

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Presentation transcript:

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death occurs or the 5-year period ends. Dotted boxes are events that cause a change of state. Each cycle is 6 months. The health states are equivalent for BMS and DES; however, probabilities and initial costs vary with the strategy. BMS, bare-metal stents; DES, drug-eluting stents; MI, myocardial infarction; PCI, percutaneous coronary intervention. Louise Baschet et al. Open Heart 2016;3:e000445 ©2016 by British Cardiovascular Society